Anna-Barbara Moscicki1, Brad Karalius2, Katherine Tassiopoulos2, Tzy-Jyun Yao3, Denise L Jacobson3, Kunjal Patel2, Murli Purswani4, George R Seage2. 1. Department of Pediatrics, Division of Adolescent Medicine, University of California, Los Angeles. 2. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 4. Division of Pediatric Infectious Disease, Bronx-Lebanon Hospital Center, Icahn School of Medicine at Mount Sinai, New York.
Abstract
BACKGROUND: Persons who are infected with human immunodeficiency virus (HIV) are at high risk of human papillomavirus (HPV)-associated cancers. The objectives are to compare antibody titers to HPV 6, 11, 16, and 18 and rate of abnormal cytology between perinatally HIV-infected (PHIV) and perinatally HIV-exposed, uninfected (PHEU) youth. METHODS: This is a prospective observational cohort study of HPV4 vaccinated youth performed as part of the multicenter Pediatric HIV/AIDS Cohort Study Adolescent Master Protocol. Seroconversion and geometric mean titer (GMT) against HPV types 6, 11, 16, and 18 were calculated. Vaccine effectiveness included rates of abnormal cervical cytology and genital warts. RESULTS: Seroconversion to HPV 6, 11, 16, and 18 occurred in 83%, 84%, 90%, and 62% of 310 vaccinated PHIV youth compared to 94%, 96%, 99%, and 87% of 148 vaccinated PHEU youth, respectively (P < .05 for all comparisons). GMTs were lower in the PHIV vs PHEU within each category of HPV4 doses received. Higher GMTs were associated with younger age, lower HIV type 1 RNA viral load, and higher CD4% at first HPV4 vaccination, as well as shorter duration between last vaccine dose and antibody specimen. Abnormal cytology occurred in 33 of 56 PHIV and 1 of 7 PHEU sexually active vaccinated females, yielding incidence rates per 100 person-years of 15.0 (10.9 to 20.6) and 2.9 (0.4 to 22.3), respectively. CONCLUSION: Antibody titers to HPV4 were lower for all serotypes in PHIV compared to PHEU youth. Protection against abnormal cytology was also diminished in sexually active PHIV females.
BACKGROUND:Persons who are infected with human immunodeficiency virus (HIV) are at high risk of human papillomavirus (HPV)-associated cancers. The objectives are to compare antibody titers to HPV 6, 11, 16, and 18 and rate of abnormal cytology between perinatally HIV-infected (PHIV) and perinatally HIV-exposed, uninfected (PHEU) youth. METHODS: This is a prospective observational cohort study of HPV4 vaccinated youth performed as part of the multicenter Pediatric HIV/AIDS Cohort Study Adolescent Master Protocol. Seroconversion and geometric mean titer (GMT) against HPV types 6, 11, 16, and 18 were calculated. Vaccine effectiveness included rates of abnormal cervical cytology and genital warts. RESULTS: Seroconversion to HPV 6, 11, 16, and 18 occurred in 83%, 84%, 90%, and 62% of 310 vaccinated PHIV youth compared to 94%, 96%, 99%, and 87% of 148 vaccinated PHEU youth, respectively (P < .05 for all comparisons). GMTs were lower in the PHIV vs PHEU within each category of HPV4 doses received. Higher GMTs were associated with younger age, lower HIV type 1 RNA viral load, and higher CD4% at first HPV4 vaccination, as well as shorter duration between last vaccine dose and antibody specimen. Abnormal cytology occurred in 33 of 56 PHIV and 1 of 7 PHEU sexually active vaccinated females, yielding incidence rates per 100 person-years of 15.0 (10.9 to 20.6) and 2.9 (0.4 to 22.3), respectively. CONCLUSION: Antibody titers to HPV4 were lower for all serotypes in PHIV compared to PHEU youth. Protection against abnormal cytology was also diminished in sexually active PHIV females.
Authors: Elmar A Joura; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; Xavier Bosch; Joakim Dillner; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Richard M Haupt; Eliav Barr Journal: Vaccine Date: 2008-10-16 Impact factor: 3.641
Authors: George K Siberry; Kunjal Patel; William J Bellini; Brad Karalius; Murli U Purswani; Sandra K Burchett; William A Meyer; Sun Bae Sowers; Angela Ellis; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Michael Herfs; Yusuke Yamamoto; Anna Laury; Xia Wang; Marisa R Nucci; Margaret E McLaughlin-Drubin; Karl Münger; Sarah Feldman; Frank D McKeon; Wa Xian; Christopher P Crum Journal: Proc Natl Acad Sci U S A Date: 2012-06-11 Impact factor: 11.205
Authors: Erna Milunka Kojic; Minhee Kang; Michelle S Cespedes; Triin Umbleja; Catherine Godfrey; Reena T Allen; Cynthia Firnhaber; Beatriz Grinsztejn; Joel M Palefsky; Jennifer Y Webster-Cyriaque; Alfred Saah; Judith A Aberg; Susan Cu-Uvin Journal: Clin Infect Dis Date: 2014-04-09 Impact factor: 9.079
Authors: Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson Journal: Lancet Infect Dis Date: 2015-03-03 Impact factor: 25.071
Authors: Michael J Silverberg; Wendy A Leyden; Jennifer O Lam; Chun R Chao; Steven E Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Karen K Smith-McCune; George F Sawaya Journal: Vaccine Date: 2020-05-20 Impact factor: 3.641
Authors: Gad Murenzi; Fabienne Shumbusho; Natasha Hansen; Athanase Munyaneza; Julia C Gage; Benjamin Muhoza; Faustin Kanyabwisha; Amanda Pierz; Patrick Tuyisenge; Kathryn Anastos; Philip E Castle Journal: BMJ Open Date: 2022-08-25 Impact factor: 3.006